Autonomy supported learning for Parkinson's (NCT05960331)

Improve upper limb motor learning

Trial ID
NCT05960331
Official Title
Influence of Autonomy on Motor Learning in People With Parkinson's Disease
Goal
Improve upper limb motor learning
Phase
NA
Status
RECRUITING
Sponsor
National Taiwan University Hospital
Study Type
INTERVENTIONAL
Enrollment
72 participants
Conditions
Parkinson Disease
Interventions
Autonomy supported learning, Practice with predetermined feedback

Summary For Families

The goal is to see whether giving people with Parkinson's more control over how they practice movements helps them learn and retain motor skills better, which could make rehabilitation and everyday tasks easier. Participants either use autonomy-supported learning, where they choose aspects of practice and when they receive feedback to boost motivation and engagement and promote stronger motor memory, or they follow a fixed practice plan with predetermined feedback for comparison. The trial is looking for adults over 20 who can follow instructions and have reasonable cognition (MoCA ≥ 24), with no recent upper-limb surgery; people with Parkinson's dementia, severe upper-limb tremor, implanted DBS or pacemakers, seizure risk, unstable medical conditions, or pregnancy are excluded.

Locations

  • National Taiwan University Hospital, Taipei, Taiwan

Frequently Asked Questions

What is this trial testing?
This trial is studying Autonomy supported learning. The goal is to see whether giving people with Parkinson's more control over how they practice movements helps them learn and retain motor skills better, which could make rehabilitation and everyday tasks easier. Participants either use autonomy-supported learning, where they choose aspects of practice and when they receive feedback to boost motivation and engagement and promote stronger motor memory, or they follow a fixed practice plan with predetermined feedback for comparison. The trial is looking for adults over 20 who can follow instructions and have reasonable cognition (MoCA ≥ 24), with no recent upper-limb surgery; people with Parkinson's dementia, severe upper-limb tremor, implanted DBS or pacemakers, seizure risk, unstable medical conditions, or pregnancy are excluded.
Who can participate?
Participants must be at least 20 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
How long does the trial last?
This trial is estimated to last approximately 1 year and 11 months.
Can I leave the trial if I change my mind?
Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
Can my spouse or care partner come with me to visits?
In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
Will I get a placebo in this trial?
There is no placebo group. Everyone receives an active treatment; the study compares one treatment against another.
How many visits does this trial involve?
Learning will be assessed on the second day and one week later.
What procedures are involved in this trial?
Based on the protocol, this trial involves: Questionnaires & surveys (non-invasive). Confirm the full schedule with the study coordinator.

Related Reading

View on ClinicalTrials.gov